McDermott Will & Schulte advises Generare on a €20 million fundraising round | McDermott Skip to main content

McDermott Will & Schulte advises Generare on a €20 million fundraising round

Overview


McDermott Will & Schulte advised Generare, a biotechnology company that generates innovative, high-quality molecular data for drug development, on a €20 million Series A fundraising round co-led by Alven and daphni, with participation from existing investors Teampact.ventures, Galion.exe, and VIVES Partners.

This financing will enable Generare to increase its platform’s capacity tenfold, collaborate with leading partners in drug discovery and crop protection, and condense into a few years what has taken a century of exploration and discovery.

The McDermott Will & Schulte team involved in the transaction consisted of:

About Us


Leading organizations turn to global law firm McDermott Will & Schulte for a better way to address legal challenges, connect with those at the forefront, and drive stronger outcomes. Working across more than 20 offices globally, our 1,750+ lawyers act on data-driven insights, deep relationships, and unmatched industry experience to deliver on our commitment of Always Better.